{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:58:34Z","timestamp":1790639914719,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-24534820"],"award-info":[{"award-number":["RS-2025-24534820"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00438476"],"award-info":[{"award-number":["RS-2024-00438476"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25494471"],"award-info":[{"award-number":["RS-2026-25494471"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25494471"],"award-info":[{"award-number":["RS-2026-25494471"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25494471"],"award-info":[{"award-number":["RS-2026-25494471"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies. A multitarget gene therapy was developed and validated to overcome molecular heterogeneity and compensatory survival signaling in TNBC. A codon-optimized human transcriptional intermediary factor 1\u2009gamma (opti-hTIF1\u03b3) gene therapy was evaluated in ex vivo\u2013cultured patient biopsy tissues and in orthotopic and mammary intraductal mouse models, and the underlying mechanisms were investigated using pathway and immune-functional analyses. Ex vivo findings were further validated using patient-derived cells and complementary mechanistic studies, including ubiquitination assays, chromatin immunoprecipitation, and functional macrophage coculture analyses, to define the molecular basis of TIF1\u03b3-mediated antitumor activity. Transduction of opti-hTIF1\u03b3 to ex vivo-cultured biopsy tissues from TNBC patients suppressed epithelial-to-mesenchymal transition and proliferation while inducing apoptosis. In orthotopic and mammary intraductal mouse models, opti-hTIF1\u03b3 effectively suppressed tumor growth and lung metastasis. Mechanistically, opti-hTIF1\u03b3 inhibits \u03b2-catenin via ubiquitination-dependent degradation and inhibits the SMAD-dependent TGF\u03b2 pathway by binding to SMAD2\/3. In parallel, it suppresses the SMAD-independent TGF\u03b2 pathway via ubiquitination and caspase-3-associated degradation of STAT3, leading to the inhibition of TAK1. Furthermore, opti-hTIF1\u03b3 downregulates STAT3-dependent immune modulators such as CD47 and CXCL5 in TNBC, enhancing macrophage phagocytosis. These findings position opti-hTIF1\u03b3 as a promising multitarget gene therapeutic strategy for TNBC through concurrent suppression of tumorigenic signaling and reprogramming of the immune landscape.<\/jats:p>","DOI":"10.1038\/s41392-026-02977-x","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:01:48Z","timestamp":1790636508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-6653","authenticated-orcid":false,"given":"Hyomin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9309-7874","authenticated-orcid":false,"given":"Tae Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunji","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areum","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dodam","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Joon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8489-271X","authenticated-orcid":false,"given":"Eun Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-5329","authenticated-orcid":false,"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2977_CR1","first-page":"101","volume":"21","author":"AK Dogra","year":"2025","unstructured":"Dogra, A. K., Prakash, A., Gupta, S. & Gupta, M. Prognostic significance and molecular classification of triple negative breast cancer: a systematic review. Eur J Breast Health 21, 101\u201314 (2025).","journal-title":"Eur J Breast Health"},{"key":"2977_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8, 95 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"2977_CR3","doi-asserted-by":"publisher","first-page":"13518","DOI":"10.3390\/ijms252413518","volume":"25","author":"M Pont","year":"2024","unstructured":"Pont, M., Marques, M. & Sorolla, A. Latest therapeutical approaches for triple-negative breast cancer: from preclinical to clinical research. Int J Mol Sci 25, 13518 (2024).","journal-title":"Int J Mol Sci"},{"key":"2977_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116850","volume":"236","author":"P Garg","year":"2025","unstructured":"Garg, P. et al. Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for breast cancer therapy. Biochem Pharm 236, 116850 (2025).","journal-title":"Biochem Pharm"},{"key":"2977_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. TGF-beta signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol 15, 135 (2022).","journal-title":"J Hematol Oncol"},{"key":"2977_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P Song","year":"2024","unstructured":"Song, P. et al. Wnt\/beta-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol 17, 46 (2024).","journal-title":"J Hematol Oncol"},{"key":"2977_CR7","first-page":"321","volume":"4","author":"N Fultang","year":"2021","unstructured":"Fultang, N., Chakraborty, M. & Peethambaran, B. Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist 4, 321\u201342 (2021).","journal-title":"Cancer Drug Resist"},{"key":"2977_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovic","year":"2019","unstructured":"Nedeljkovic, M. & Damjanovic, A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells 8, 957 (2019).","journal-title":"Cells"},{"key":"2977_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/cancers17050755","volume":"17","author":"K Berkley","year":"2025","unstructured":"Berkley, K., Zalejski, J. & Sharma, A. Targeting STAT3 for cancer therapy: focusing on Y705, S727, or dual inhibition?. Cancers (Basel) 17, 755 (2025).","journal-title":"Cancers (Basel)"},{"key":"2977_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya, W. L. et al. Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev 85, 26\u201342 (2025).","journal-title":"Cytokine Growth Factor Rev"},{"key":"2977_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu, Y., Dong, Z. & Liu, K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res 43, 23 (2024).","journal-title":"J Exp Clin Cancer Res"},{"key":"2977_CR12","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.2174\/0929867328666210720143721","volume":"28","author":"S Dallavalasa","year":"2021","unstructured":"Dallavalasa, S. et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis - current status. Curr Med Chem 28, 8203\u20138236 (2021).","journal-title":"Curr Med Chem"},{"key":"2977_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 26, 78 (2019).","journal-title":"J Biomed Sci"},{"key":"2977_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied, M., Ho, W. W., Ginhoux, F. & Bleriot, C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol 20, 983\u201392 (2023).","journal-title":"Cell Mol Immunol"},{"key":"2977_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s43018-021-00267-9","volume":"2","author":"K Zhai","year":"2021","unstructured":"Zhai, K. et al. Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells. Nat Cancer 2, 1136\u201351 (2021).","journal-title":"Nat Cancer"},{"key":"2977_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.molcel.2011.05.020","volume":"43","author":"E Agricola","year":"2011","unstructured":"Agricola, E., Randall, R. A., Gaarenstroom, T., Dupont, S. & Hill, C. S. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43, 85\u201396 (2011).","journal-title":"Mol Cell"},{"key":"2977_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.991","volume":"12","author":"D Moon","year":"2022","unstructured":"Moon, D. et al. Smart gene therapeutics for selective targeting of myofibroblasts derived from hepatic stellate cells and limited expression under inflamed conditions. Clin Transl Med 12, e991 (2022).","journal-title":"Clin Transl Med"},{"key":"2977_CR18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190402","volume":"217","author":"EJ Lee","year":"2020","unstructured":"Lee, E. J. et al. Hepatic stellate cell-specific knockout of transcriptional intermediary factor 1gamma aggravates liver fibrosis. J Exp Med 217, e20190402 (2020).","journal-title":"J Exp Med"},{"key":"2977_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3389\/fonc.2019.00979","volume":"9","author":"C Yu","year":"2019","unstructured":"Yu, C., Ding, Z., Liang, H., Zhang, B. & Chen, X. The roles of TIF gamma in cancer. Front Oncol. 9, 979 (2019).","journal-title":"Front Oncol"},{"key":"2977_CR20","first-page":"3685","volume":"19","author":"F Cai","year":"2019","unstructured":"Cai, F. et al. Prognostic role of Tif1gamma expression and circulating tumor cells in patients with breast cancer. Mol Med Rep 19, 3685\u201395 (2019).","journal-title":"Mol Med Rep"},{"key":"2977_CR21","doi-asserted-by":"publisher","first-page":"e0198143","DOI":"10.1371\/journal.pone.0198143","volume":"13","author":"A Ghosh","year":"2018","unstructured":"Ghosh, A. et al. MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. PLoS One 13, e0198143 (2018).","journal-title":"PLoS One"},{"key":"2977_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7156","volume":"6","author":"J Xue","year":"2015","unstructured":"Xue, J. et al. Tumour suppressor TRIM33 targets nuclear beta-catenin degradation. Nat Commun 6, 6156 (2015).","journal-title":"Nat Commun"},{"key":"2977_CR23","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/cdd.2014.123","volume":"21","author":"SR Mihaly","year":"2014","unstructured":"Mihaly, S. R., Ninomiya-Tsuji, J. & Morioka, S. TAK1 control of cell death. Cell Death Differ 21, 1667\u201376 (2014).","journal-title":"Cell Death Differ"},{"key":"2977_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.onc.1210768","volume":"27","author":"A Safina","year":"2008","unstructured":"Safina, A., Ren, M. Q., Vandette, E. & Bakin, A. V. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 27, 1198\u2013207 (2008).","journal-title":"Oncogene"},{"key":"2977_CR25","doi-asserted-by":"publisher","first-page":"1610592","DOI":"10.3389\/pore.2022.1610592","volume":"28","author":"M Stenckova","year":"2022","unstructured":"Stenckova, M., Nenutil, R., Vojtesek, B. & Coates, P. J. Stat3 tyrosine 705 and serine 727 phosphorylation associate with clinicopathological characteristics and distinct tumor cell phenotypes in triple-negative breast cancer. Pathol Oncol Res 28, 1610592 (2022).","journal-title":"Pathol Oncol Res"},{"key":"2977_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A Potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498\u2013511 (2019).","journal-title":"Cancer Cell"},{"key":"2977_CR27","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1128\/JVI.77.11.6385-6393.2003","volume":"77","author":"CM Ulane","year":"2003","unstructured":"Ulane, C. M., Rodriguez, J. J., Parisien, J. P. & Horvath, C. M. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 77, 6385\u201393 (2003).","journal-title":"J Virol"},{"key":"2977_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-29","volume":"7","author":"JR Matthews","year":"2007","unstructured":"Matthews, J. R., Watson, S. M., Tevendale, M. C., Watson, C. J. & Clarke, A. R. Caspase-dependent proteolytic cleavage of STAT3alpha in ES cells, in mammary glands undergoing forced involution and in breast cancer cell lines. BMC Cancer 7, 29 (2007).","journal-title":"BMC Cancer"},{"key":"2977_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2977_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther 8, 104 (2023).","journal-title":"Signal Transduct Target Ther"},{"key":"2977_CR31","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1038\/onc.2012.444","volume":"32","author":"YL Hsu","year":"2013","unstructured":"Hsu, Y. L., Hou, M. F., Kuo, P. L., Huang, Y. F. & Tsai, E. M. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK\/MSK1\/Elk-1\/Snail signaling pathway. Oncogene 32, 4436\u201347 (2013).","journal-title":"Oncogene"},{"key":"2977_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cac2.12010","volume":"40","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun 40, 69\u201380 (2020).","journal-title":"Cancer Commun"},{"key":"2977_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41388-019-1088-8","volume":"39","author":"H Mukhopadhyay","year":"2020","unstructured":"Mukhopadhyay, H. & Lee, N. Y. Multifaceted roles of TAK1 signaling in cancer. Oncogene 39, 1402\u201313 (2020).","journal-title":"Oncogene"},{"key":"2977_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O'Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15, 234\u201348 (2018).","journal-title":"Nat Rev Clin Oncol"},{"key":"2977_CR35","doi-asserted-by":"publisher","first-page":"216205","DOI":"10.1016\/j.canlet.2023.216205","volume":"564","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. Reprogramming of TAMs via the STAT3\/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett 564, 216205 (2023).","journal-title":"Cancer Lett"},{"key":"2977_CR36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240111","volume":"221","author":"Y Xue","year":"2024","unstructured":"Xue, Y. et al. TET2\u2013STAT3\u2013CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition. J Exp Med 221, e20240111 (2024).","journal-title":"J Exp Med"},{"key":"2977_CR37","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18, e3000411 (2020).","journal-title":"PLoS Biol"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02977-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:01:49Z","timestamp":1790636509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02977-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2977"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02977-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"413"}}